Stock Region Penny Picks
Penny Stocks That Are Making Moves
Penny Stocks That Are Making Moves
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is for informational and entertainment purposes only. The content provided is not financial advice, and you should not construe any such information or other material as legal, tax, investment, financial, or other advice. All content is information of a general nature and does not address the circumstances of any particular individual or entity. Please consult a licensed professional before making any financial decisions.
Your Friday Afternoon Market Wrap-Up
Happy Friday, everyone! The market has been a wild ride this week, but some interesting stories are popping up that we just have to talk about. We’ve been digging through the news feeds to find the tickers with some real buzz around them. Let’s break down what’s moving and why.
$MBOT - Microbot Medical, Inc.
It looks like H.C. Wainwright & Co. is standing firm on its conviction for Microbot Medical. They’ve reiterated their “Buy” rating and are holding a $12 price target. With the stock currently trading around $2.48, that’s a bold statement. They clearly see some massive upside potential. A price target that far above the current price suggests they believe a significant catalyst is on the horizon. Definitely one to watch to see if their prediction has legs.
$SMX - SMX (Security Matters) Public Limited Company
SMX seems to be making a huge splash in the commodities world. The headline says it all: “SMX Supplied the Proof and Now DMCC is Rewriting the Gold Standard.” This sounds like a game-changer. When you’re talking about altering how a massive entity like the Dubai Multi Commodities Centre handles gold, you’re talking about disrupting a multi-billion dollar industry. This could be a fundamental shift, and SMX is right at the center of it.
$VUZI - Vuzix Corporation
Vuzix is showing some serious momentum heading into the end of the year. Shipments of their AI-powered smart glasses to a major global online retailer are nearing the $1 million mark for the fourth quarter. This isn’t just a pilot program; it’s a significant order that points to real-world adoption of their tech. It’s great to see Vuzix converting its innovative technology into substantial revenue.
$ABVE - Above Food Ingredients Inc.
Now this is a mouthful of good news. Above Food has announced major strategic milestones, including progress on its merger with Palm Global. On top of that, they’re expecting profits to exceed $30 million for the fiscal year ending in January 2026. This company is firing on all cylinders—merging, growing, and forecasting strong profitability. That’s a powerful combination that investors love to see.
$ENTO / $GRDX - Entero Therapeutics, Inc. / GridAI Technologies Corp.
Big changes are coming for Entero Therapeutics. The company is rebranding itself as GridAI Technologies Corp. and will trade under the new ticker symbol “GRDX” starting this Monday, December 1st. This name change signals a strategic pivot, likely towards artificial intelligence. It’s a fresh start and a new story for the company. Keep an eye on GRDX next week to see how the market reacts to its new identity.
$WBUY - Webuy Global Ltd.
Interesting move from Webuy Global. They’re settling a debt of over $600,000 by issuing shares instead of using cash. This can be a smart way for a growing company to preserve its cash reserves for operations and expansion. While it can dilute existing shareholders slightly, it shows a strategic approach to managing the balance sheet.
That’s a wrap for this week! Some of these stocks are telling compelling stories. As always, do your own research and keep a close eye on the market. Have a great weekend!
Reminder: Investing in the stock market involves risk. The value of your investment can go down as well as up. Past performance is not indicative of future results. All trades are at your own risk. This is not a recommendation to buy or sell any security.